(IBD) Northern Lights Fund Trust - Ratings and Ratios

Exchange: NYSE ARCA • Country: USA • Currency: USD • Type: Etf • ISIN: US1416376036

IBD: Large, Capitalization, Corporate, Bonds, ETF

The Inspire Corporate Bond Impact ETF (IBD) is an exchange-traded fund that focuses on investing in large-cap, investment-grade corporate bonds with a positive impact score. The funds investment strategy is centered around tracking an index that comprises domestic corporate bonds issued by companies that meet specific criteria, including a minimum Inspire Impact Score of zero.

The Inspire Impact Score is a proprietary metric that assesses a companys environmental, social, and governance (ESG) performance. By investing in bonds with a score of zero or higher, the fund aims to support companies that demonstrate a positive impact on society and the environment. This approach allows investors to align their fixed-income investments with their values while seeking returns.

From a technical analysis perspective, the funds price action suggests a stable trend, with the short-term and long-term moving averages converging. The 20-day SMA is at 23.61, while the 50-day SMA is at 23.60, indicating a relatively flat price trajectory. However, the 200-day SMA is at 23.35, suggesting a gradual upward trend over the longer term. The ATR of 0.25, equivalent to 1.05%, indicates moderate volatility. Given the current price of 23.70, we can expect the fund to continue its stable trend, potentially testing the 52-week high of 23.86 in the near term.

Combining the technical analysis with fundamental data, we can forecast that the Inspire Corporate Bond Impact ETF will likely maintain its current price level, potentially appreciating towards the 52-week high. The funds AUM of $388.25M suggests a reasonable level of liquidity, which can help to support the funds stability. As interest rates and credit markets evolve, the funds focus on investment-grade corporate bonds is likely to continue to attract investors seeking stable returns with a positive impact.

Looking ahead, if the overall corporate bond market continues to perform well, and the funds underlying holdings maintain their credit quality, we can expect the IBD ETF to remain a stable investment option. However, any significant changes in interest rates or credit spreads could impact the funds performance. As such, investors should continue to monitor the funds technical and fundamental trends to make informed investment decisions.

Additional Sources for IBD ETF

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle

IBD ETF Overview

Market Cap in USD 384m
Category Corporate Bond
TER 0.44%
IPO / Inception 2017-07-10

IBD ETF Ratings

Growth Rating 15.2
Fundamental -
Dividend Rating 73.0
Rel. Strength 5.72
Analysts -
Fair Price Momentum 23.59 USD
Fair Price DCF -

IBD Dividends

Dividend Yield 12m 4.32%
Yield on Cost 5y 4.42%
Annual Growth 5y 17.72%
Payout Consistency 93.0%
Payout Ratio %

IBD Growth Ratios

Growth Correlation 3m 77.4%
Growth Correlation 12m 76.1%
Growth Correlation 5y -8.9%
CAGR 5y 0.81%
CAGR/Max DD 5y 0.05
Sharpe Ratio 12m 2.89
Alpha 3.45
Beta -0.015
Volatility 6.26%
Current Volume 67.2k
Average Volume 20d 49.1k
What is the price of IBD shares?
As of July 01, 2025, the stock is trading at USD 24.01 with a total of 67,204 shares traded.
Over the past week, the price has changed by +0.74%, over one month by +1.54%, over three months by +2.19% and over the past year by +7.81%.
Is Northern Lights Fund Trust a good stock to buy?
Neither. Based on ValueRay´s Analyses, Northern Lights Fund Trust is currently (July 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of 15.22 and therefor a technical neutral rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of IBD is around 23.59 USD . This means that IBD is currently overvalued and has a potential downside of -1.75%.
Is IBD a buy, sell or hold?
Northern Lights Fund Trust has no consensus analysts rating.
What are the forecasts for IBD share price target?
According to our own proprietary Forecast Model, IBD Northern Lights Fund Trust will be worth about 25.5 in July 2026. The stock is currently trading at 24.01. This means that the stock has a potential upside of +6.12%.
Issuer Target Up/Down from current
Wallstreet Target Price - -
Analysts Target Price - -
ValueRay Target Price 25.5 6.1%